Encontrados 3 documentos, a visualizar página 1 de 1
Impact of EGFR genetic variants on glioma risk and patient outcome
Costa, Bruno Marques; Pereira, Marta Viana; Fernandes, Ricardo; Costa, S.; Linhares, Paulo; Vaz, Rui; Pinheiro, Céline; Lima, Jorge; Soares, PaulaB.M. Costa and M. Viana-Pereira contributed equally to this work; The authors thank the Immunochemotherapy Department of Hospital S. Marcos, and Clinica Laboratorial Dr. Edgar Botelho Moniz, S. Tirso, Portugal, for their helpful assistance in the management of controls ; BACKGROUND: The epidermal growth factor receptor (EGFR) regulates important cellular processes and is frequently implicated in human tumors. ...
Prognostic value of MGMT promoter methylation in glioblastoma patients treated ...
Costa, Bruno Marques; Caeiro, Cláudia; Guimarães, Inês; Martinho, Olga; Jaraquemada, Teresa; Augusto, Isabel; Castro, Lígia; Osório, LígiaGlioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-speci...
TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant th...
Lima-Ramos, Vítor; Pacheco-Figueiredo, Luís; Costa, Sandra Maria Araújo da; Pardal, Fernando; Silva, Ana; Amorim, Júlia; Lopes, José Manuel; Reis, R. M.TP53 is a key tumor suppressor gene that encodes a transcriptional factor involved in several cellular mechanisms, including growth arrest, DNA repair, and induction of apoptosis. In addition to TP53 gene mutations, a common polymorphism, Arg72Pro, has been involved in the carcinogenesis process. The Pro72 variant has been associated with a slower induction of apoptosis and may influence the risk of cancer deve...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||